Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
3
×
Tags
boston blog main
life sciences
3
×
national blog main
new york blog main
new york top stories
regeneron pharmaceuticals
3
×
alirocumab
alnylam pharmaceuticals
biotech
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
national
national top stories
raleigh-durham blog main
raleigh-durham top stories
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alex azar
ambys medicines
american patients first
amgen
amicus therapeutics
ampio pharmaceuticals
angelman syndrome
What
drug
long
3
×
drugs
prices
afternoon
alnylam
anticipated
aren’t
awaited
based
bio
blueprint
cholesterol
cost
cut
data
details
developers
evidence
fda
gene
heart
help
house
imminent
lasting
looms
lower
lowering
meant
medco
medicare
medicines
moves
new
news
noteworthy
partner
patients
pharmaceuticals
Language
Current search:
long
×
photo
×
" life sciences "
×
" regeneron pharmaceuticals "
×
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details
